Patent intelligence · US
US 10632255
Drug infusion device
Drug infusion device
Patent details — US 10632255
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 28, 2020
- Expiration
- Apr 23, 2040
- Applicant
- MILESTONE SCIENTIFIC, INC.
- Claims
- 12
- CPC classes
- A61K, A61K38/4893, A61K9/0019
Quick answer
US 10632255 (Drug infusion device) is held by MILESTONE SCIENTIFIC, INC.. Status: granted. Granted Apr 28, 2020. Expires Apr 23, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MILESTONE SCIENTIFIC, INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K38/4893, A61K9/0019
More from MILESTONE SCIENTIFIC, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12257224
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
granted -
US 10308609
Bicyclic compounds
granted -
US 10251851
Bicyclic analgesic compounds
granted -
US 10117848
Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
granted -
US 10010524
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010523
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010522
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted
Frequently asked questions
What is US patent 10632255?
US 10632255 (Drug infusion device) is held by MILESTONE SCIENTIFIC, INC.. Status: granted. Granted Apr 28, 2020. Expires Apr 23, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10632255?
MILESTONE SCIENTIFIC, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 10632255 expire?
Our index shows an expiration date of Apr 23, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.